Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Keep Inspiring

Don’t let your disease define you

Tecartus After Outpatient Lymphodepletion Safe, Effective in B-ALL and MCL

December 16th 2024, 4:00pm

Article

Outpatient lymphodepletion followed by Tecartus was found to be safe and effective in treating B-cell acute lymphoblastic leukemia and mantle cell lymphoma.

Survival Outcomes Not Improved With Autologous Stem Cell Transplant in MCL

December 11th 2024, 1:11am

Article

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

Heart Risk May Occur Less With Some BTK Inhibitors in B-Cell Blood Cancers

December 9th 2024, 11:00pm

Article

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.

Parenting and Cancer: How Much Do Kids Need to Know?

November 26th 2024, 10:00pm

Article

Musician Danielia Cotton and her partner, attorney Sam Roberts, discuss how much they’ve shared with their daughter about their cancer journeys.

Columvi Shows High Response Rates and Safety in R/R Mantle Cell Lymphoma

November 19th 2024, 2:00pm

Article

Treatment with Columvi showed a manageable safety profile in heavily pre-treated patients with relapsed or refractory mantle cell lymphoma.

Boruzu Approved by FDA For Multiple Myeloma, Mantle Cell Lymphoma

September 6th 2024, 1:48pm

Article

Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma.

CAR-T Cell Therapy for Relapsed, Refractory Mantle Cell Lymphoma Fills Unmet Need

July 24th 2024, 9:00pm

Article

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said.

Finding a Second Opinion Was a Pivotal Moment in My Cancer Experience

July 18th 2024, 1:00pm

Article

From second opinions to research and asking for help, here are some pivotal lessons I learned after a mantle cell lymphoma diagnosis.

FDA Approves Breyanzi for Relapsed, Refractory MCL

May 30th 2024, 4:42pm

Article

The CAR-T cell therapy, Breyanzi, has received FDA approval for relapsed or refractory mantle cell lymphoma.

Calquence Regimen Improves Outcomes in Frontline Mantle Cell Lymphoma

May 2nd 2024, 9:00pm

Article

Adding Calquence to standard-of-care chemoimmunotherapy improved progression-free survival in patients with previously untreated mantle cell lymphoma.